section name header

Pronunciation

floo-KON-a-zole

Classifications

Therapeutic Classification: antifungals (systemic)

Indications

REMS

Unlabeled Use:

Action

Therapeutic Effects:

Spectrum:

Pharmacokinetics

Absorption: Well absorbed after oral administration.

Distribution: Widely distributed, good penetration into CSF, saliva, sputum, vaginal fluid, skin, eye, and peritoneum.

Metabolism/Excretion: >80% excreted unchanged by the kidneys; <10% metabolized by the liver.

Half-life: Premature neonates: 46–74 hr; Children: 19–25 hr (PO) and 15–17 hr (IV); Adults: 30 hr (↑ in renal impairment).

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2–4 hr24 hr
IVrapidend of infusion24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: QT interval prolongation, TORSADES DE POINTES.

Derm: STEVENS-JOHNSON SYNDROME.

Endo: adrenal insufficiency, hypertriglyceridemia, hypokalemia.

GI: abdominal discomfort, diarrhea, HEPATOTOXICITY, nausea, vomiting.

Neuro: dizziness, headache, seizures.

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS).

Interactions

Drug-Drug:

Route/Dosage

see Calculator

Oropharyngeal Candidiasis

Renal Impairment

Esophageal Candidiasis

Renal Impairment

Vaginal Candidiasis

Systemic Candidiasis

Renal Impairment

Cryptococcal Meningitis

Renal Impairment

Prevention of Candidiasis after Bone Marrow Transplant

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Diflucan

Pill Image

fluconazole_195_8739.jpg

Code

NDC Code*